Companies like Pfizer, AstraZeneca, Sanofi, and Roche are investing in next-gen GLP-1s, dual and triple agonists, and even oral formulations to compete in whats now a multi-billion-dollar therapeutic category
Compounded semaglutide Compounded semaglutide is available without insurance
Skipping doses, restarting without guidance, or changing your schedule may increase the likelihood of digestive symptoms returning
In diabetes care, they remain part of a structured, guideline-driven approach focused on glycemic control and long-term complication prevention
Swissmedic issues warning about the increasing number of falsified, misleading or unauthorised weight loss products currently on offer that make reference to GLP-1 active substances
Grieco M, et al